Interchangeable Insulins: FDA Holds Public Meeting

Although insulin biosimilars and interchangeable products will not hit the US market until March 2020 at the earliest, the US Food and Drug Administration (FDA) on Monday held a public meeting to hear from various companies and stakeholders on the standards for establishing interchangeability and what patient experience to consider.